John Harold Kanter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John Harold Kanter has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Geoffrey T. Manley
Department of Neurosurgery, University of California, San Francisco, CA, United States; Zuckerberg San Francisco General Hospital, San Francisco, CA, United States
4 shared publicationsAnthony M. DiGiorgio
Department of Neurosurgery, University of California, San Francisco, CA, United States; Zuckerberg San Francisco General Hospital, San Francisco, CA, United States
3 shared publicationsMichael C. Huang
Department of Neurosurgery, University of California, San Francisco, CA, United States; Zuckerberg San Francisco General Hospital, San Francisco, CA, United States; Department of Neurosurgery, San Francisco Veterans Affairs Medical Center, San Francisco, CA, United States
3 shared publicationsAbel Torres-Espin
Brain and Spinal Injury Center, Zuckerberg San Francisco General Hospital, San Francisco, California, USA
2 shared publicationsAdam C. Glaser
Brigham and Women's Hospital
2 shared publicationsDavid O. Okonkwo
Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
2 shared publications
Latest Publications
- Open Access
Epidural versus Transcutaneous Spinal Cord Stimulation for Motor Recovery after Spinal Cord Injury: A Comparative Analysis
Spinal cord injury (SCI) is a devastating neurological injury that results in the profound loss of voluntary motor function and marked reduction in quality of life. Rehabilitation remains as the standard of care for recovery after SCI; however, it often falls short in recovering meaningful motor function. Spinal cord stimulation (SCS) has emerged as a promising neurostimulation approach to fill this gap and recover lost voluntary motor function. Two main approaches of SCS have been designed and implemented for human use: epidural and transcutaneous SCS. Over the last two decades, several clinical studies have shown convincing evidence that both epidural and transcutaneous SCS can be used in conjunction with rehabilitation to improve motor function of individuals after SCI. Yet fundamental clinical questions remain unanswered: when should clinicians choose epidural or transcutaneous SCS, which technique provides the most durable outcomes, and for whom is each therapy best? Without these answers, widespread and meaningful adoption of either approach into clinical practice will remain limited. To address these questions, in this Review, we define the distinct therapeutic goals, intended use cases, clinical parameters, and responder profiles for both epidural and transcutaneous SCS to guide their eventual adoption into clinical practice. We found that indeed epidural and transcutaneous SCS serve distinct therapeutic roles. Epidural SCS is designed as an assistive therapy that can restore muscle activity and single joint movements immediately within one week of implantation, while transcutaneous SCS is designed as a long-term therapeutic device with cumulative functional gains observed over treatment periods of up to 18 weeks. Lastly, epidural SCS produced benefits for all participants (AIS A-D) despite the extent of their injury, while transcutaneous SCS only consistently benefits individuals with incomplete motor injuries (AIS C-D).
Open AccessEpidural versus Transcutaneous Spinal Cord Stimulation for Motor Recovery after Spinal Cord Injury: A Comparative Analysis
Spinal cord injury (SCI) is a devastating neurological injury that results in the profound loss of voluntary motor function and marked reduction in quality of life. Rehabilitation remains as the standard of care for recovery after SCI; however, it often falls short in recovering meaningful motor function. Spinal cord stimulation (SCS) has emerged as a promising neurostimulation approach to fill this gap and recover lost voluntary motor function. Two main approaches of SCS have been designed and implemented for human use: epidural and transcutaneous SCS. Over the last two decades, several clinical studies have shown convincing evidence that both epidural and transcutaneous SCS can be used in conjunction with rehabilitation to improve motor function of individuals after SCI. Yet fundamental clinical questions remain unanswered: when should clinicians choose epidural or transcutaneous SCS, which technique provides the most durable outcomes, and for whom is each therapy best? Without these answers, widespread and meaningful adoption of either approach into clinical practice will remain limited. To address these questions, in this Review, we define the distinct therapeutic goals, intended use cases, clinical parameters, and responder profiles for both epidural and transcutaneous SCS to guide their eventual adoption into clinical practice. We found that indeed epidural and transcutaneous SCS serve distinct therapeutic roles. Epidural SCS is designed as an assistive therapy that can restore muscle activity and single joint movements immediately within one week of implantation, while transcutaneous SCS is designed as a long-term therapeutic device with cumulative functional gains observed over treatment periods of up to 18 weeks. Lastly, epidural SCS produced benefits for all participants (AIS A-D) despite the extent of their injury, while transcutaneous SCS only consistently benefits individuals with incomplete motor injuries (AIS C-D).
- 26 November 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 261, 109265
Factors associated with venous thromboembolism in hospitalized traumatic brain injury patients with external ventricular drains: Retrospective cohort study
- 26 November 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 261, 109265
Factors associated with venous thromboembolism in hospitalized traumatic brain injury patients with external ventricular drains: Retrospective cohort study
- 15 October 2025
- Published by Taylor & Francis in The Journal of Spinal Cord Medicine
- p. 1-12
Spinal cord injury is an independent risk factor for acute kidney injury in traumatic spine-injured patients in the National Trauma Data Bank
Patients with spine injuries are at risk of acute kidney injury (AKI) through several mechanisms. This study aims to assess the rate of severe AKI in a nationally representative sample of patients with spine injuries and determine whether SCI is an independent risk factor. We conducted a cohort study utilizing the National Trauma Databank (NTDB) Patients included were 18 years or older with cervical or thoracic spine injuries (spine fractures and/or spinal cord injury) based on International Classification of Disease (ICD) codes from 2017 to 2022. Patients with pre-existing renal impairment were excluded. Logistic regression was used to determine the association between demographic and injury variables with incident AKI. 313,838 spinal injury patients were analyzed, of which 3,288 (1.05%) developed AKI. Patients with AKI were older (61 ± 19 vs. 55 ± 21 years, P < 0.001) and had more comorbidities. AKI was associated with higher Injury Severity Scores (23 ± 16 vs. 16 ± 12, P < 0.001) and increased blood product transfusions. After adjustment for confounders, SCI was independently associated with AKI (OR 1.41, 95% CI 1.28-1.55, P < 0.001). AKI patients experienced worse outcomes, including longer ICU stays, higher rates of withdrawal of care and unfavorable hospital dispositions (all P < 0.001). AKI is associated with morbidity and mortality in patients with spine injuries. Comorbidities and more severe injuries, including the presence of SCI, are associated with AKI. More work is warranted to understand mechanisms of AKI in these patients.
- 15 October 2025
- Published by Taylor & Francis in The Journal of Spinal Cord Medicine
- p. 1-12
Spinal cord injury is an independent risk factor for acute kidney injury in traumatic spine-injured patients in the National Trauma Data Bank
Patients with spine injuries are at risk of acute kidney injury (AKI) through several mechanisms. This study aims to assess the rate of severe AKI in a nationally representative sample of patients with spine injuries and determine whether SCI is an independent risk factor. We conducted a cohort study utilizing the National Trauma Databank (NTDB) Patients included were 18 years or older with cervical or thoracic spine injuries (spine fractures and/or spinal cord injury) based on International Classification of Disease (ICD) codes from 2017 to 2022. Patients with pre-existing renal impairment were excluded. Logistic regression was used to determine the association between demographic and injury variables with incident AKI. 313,838 spinal injury patients were analyzed, of which 3,288 (1.05%) developed AKI. Patients with AKI were older (61 ± 19 vs. 55 ± 21 years, P < 0.001) and had more comorbidities. AKI was associated with higher Injury Severity Scores (23 ± 16 vs. 16 ± 12, P < 0.001) and increased blood product transfusions. After adjustment for confounders, SCI was independently associated with AKI (OR 1.41, 95% CI 1.28-1.55, P < 0.001). AKI patients experienced worse outcomes, including longer ICU stays, higher rates of withdrawal of care and unfavorable hospital dispositions (all P < 0.001). AKI is associated with morbidity and mortality in patients with spine injuries. Comorbidities and more severe injuries, including the presence of SCI, are associated with AKI. More work is warranted to understand mechanisms of AKI in these patients.
- 29 September 2025
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 43 (1-2) , 1-12
Intracranial Pressure as a Dynamic Predictor of Traumatic Brain Injury Outcomes: A Scoping Review
Intracranial pressure (ICP) monitoring remains a cornerstone in the management of severe traumatic brain injury (TBI), yet its utility as a dynamic predictor of outcomes continues to evolve. We aimed to examine the role of serial ICP measurements as a potential predictor of outcomes after TBI, to combine ICP data with cerebrovascular reactivity metrics, and to highlight emerging trends in ICP modeling such as machine learning-based predictive models. We conducted a rigorous scoping review following Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews guidelines to investigate the utility of ICP monitoring as a dynamic predictor of outcomes following TBI. A systematic search of major databases identified relevant studies published between January 1, 1998, and August 1, 2024. Two reviewers identified relevant articles, and conflicts were adjudicated by a third. Data from the included studies were abstracted and synthesized. Analysis of 29 studies ( N = 5,743 patients) revealed significant associations between specific ICP patterns and clinical outcomes. Key findings included threshold-dependent mortality predictions, the value of early monitoring patterns (i.e., patterns observed within the first 72 h post-injury), and the enhancement of predictive accuracy through integration with cerebrovascular reactivity indices. Many studies now explore ICP as a multidimensional metric rather than a straightforward number, but overarching conclusions are limited by inter-study variability in analysis. The integration of advanced monitoring techniques, the use of features capturing the temporal complexity of ICP, and machine learning approaches show promise in enhancing the predictive value of ICP monitoring as a new form of precision medicine. These findings support strong associations between specific ICP dynamic patterns and mortality and functional outcomes. Standardization of protocols and validation in diverse populations remain important challenges to address in future studies.
- 29 September 2025
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 43 (1-2) , 1-12
Intracranial Pressure as a Dynamic Predictor of Traumatic Brain Injury Outcomes: A Scoping Review
Intracranial pressure (ICP) monitoring remains a cornerstone in the management of severe traumatic brain injury (TBI), yet its utility as a dynamic predictor of outcomes continues to evolve. We aimed to examine the role of serial ICP measurements as a potential predictor of outcomes after TBI, to combine ICP data with cerebrovascular reactivity metrics, and to highlight emerging trends in ICP modeling such as machine learning-based predictive models. We conducted a rigorous scoping review following Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews guidelines to investigate the utility of ICP monitoring as a dynamic predictor of outcomes following TBI. A systematic search of major databases identified relevant studies published between January 1, 1998, and August 1, 2024. Two reviewers identified relevant articles, and conflicts were adjudicated by a third. Data from the included studies were abstracted and synthesized. Analysis of 29 studies ( N = 5,743 patients) revealed significant associations between specific ICP patterns and clinical outcomes. Key findings included threshold-dependent mortality predictions, the value of early monitoring patterns (i.e., patterns observed within the first 72 h post-injury), and the enhancement of predictive accuracy through integration with cerebrovascular reactivity indices. Many studies now explore ICP as a multidimensional metric rather than a straightforward number, but overarching conclusions are limited by inter-study variability in analysis. The integration of advanced monitoring techniques, the use of features capturing the temporal complexity of ICP, and machine learning approaches show promise in enhancing the predictive value of ICP monitoring as a new form of precision medicine. These findings support strong associations between specific ICP dynamic patterns and mortality and functional outcomes. Standardization of protocols and validation in diverse populations remain important challenges to address in future studies.
- Open Access
- 16 October 2024
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 39, 100915
Clinical profile of patients with acute traumatic brain injury undergoing cranial surgery in the United States: report from the 18-centre TRACK-TBI cohort study
- 16 October 2024
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 39, 100915
Open AccessClinical profile of patients with acute traumatic brain injury undergoing cranial surgery in the United States: report from the 18-centre TRACK-TBI cohort study
- Open Access
- 30 May 2024
- Published by Springer Nature in Research Square
The Effect of Antiseizure Medication on Mortality in Spontaneous Aneurysmal Subarachnoid Hemorrhage
Background Spontaneous aneurysmal subarachnoid hemorrhage (aSAH) is a major cause of morbidity and mortality in the United States. The efficacy of early antiseizure medication (ASM) is debated. Recent literature reports seizure rates ranging from 7.8% to 15.2% following spontaneous aSAH. Current guidelines recommend use of early ASM in patients with “high-risk features,” but whether early ASM use decreases the rate of death associated with aSAH remains unclear. This study assessed whether early administration of early ASM impacts mortality rates after spontaneous aSAH. Methods We conducted a retrospective cohort study using a publicly available dataset from the Massachusetts Institute of Technology, Medical Information Mart for Intensive Care-III (MIMIC) database of all patients over the age of 18 with spontaneous aSAH resulting in an intensive care unit (ICU) admission to a major United States trauma center from 2001 to 2012. The primary exposure was receiving early ASM and primary outcome of death within 7 days. Different regression models were created to explore the association between early ASM administration within 24 hours of admission and a composite outcome of seizure and/or death within 7 days of admission. Secondary outcomes included 30-day and one-year mortality. Results Of 253 patients with spontaneous aSAH, 148 received early ASM within 24 hours. Patients who did not receive early ASM were more likely to die within 7 days of admission (adjusted odd ratio, [aOR]: 0.25 95% CI 0.09 to 0.067; P=0.006) but were less likely to have a seizure (aOR: 7.65 95% CI 2.03 to 28.89). Conclusion Early ASM administration was associated with lower rates of seizure and/or death within 7 days of admission among patients who presented to an ICU with spontaneous aSAH. These findings suggest broader use of early ASM in patients who present with spontaneous aSAH may improve early mortality.
- 30 May 2024
- Published by Springer Nature in Research Square
Open AccessThe Effect of Antiseizure Medication on Mortality in Spontaneous Aneurysmal Subarachnoid Hemorrhage
Background Spontaneous aneurysmal subarachnoid hemorrhage (aSAH) is a major cause of morbidity and mortality in the United States. The efficacy of early antiseizure medication (ASM) is debated. Recent literature reports seizure rates ranging from 7.8% to 15.2% following spontaneous aSAH. Current guidelines recommend use of early ASM in patients with “high-risk features,” but whether early ASM use decreases the rate of death associated with aSAH remains unclear. This study assessed whether early administration of early ASM impacts mortality rates after spontaneous aSAH. Methods We conducted a retrospective cohort study using a publicly available dataset from the Massachusetts Institute of Technology, Medical Information Mart for Intensive Care-III (MIMIC) database of all patients over the age of 18 with spontaneous aSAH resulting in an intensive care unit (ICU) admission to a major United States trauma center from 2001 to 2012. The primary exposure was receiving early ASM and primary outcome of death within 7 days. Different regression models were created to explore the association between early ASM administration within 24 hours of admission and a composite outcome of seizure and/or death within 7 days of admission. Secondary outcomes included 30-day and one-year mortality. Results Of 253 patients with spontaneous aSAH, 148 received early ASM within 24 hours. Patients who did not receive early ASM were more likely to die within 7 days of admission (adjusted odd ratio, [aOR]: 0.25 95% CI 0.09 to 0.067; P=0.006) but were less likely to have a seizure (aOR: 7.65 95% CI 2.03 to 28.89). Conclusion Early ASM administration was associated with lower rates of seizure and/or death within 7 days of admission among patients who presented to an ICU with spontaneous aSAH. These findings suggest broader use of early ASM in patients who present with spontaneous aSAH may improve early mortality.
- Open Access
- 3 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 2024
Neuroworsening in the Emergency Department Is a Predictor of Traumatic Brain Injury Intervention and Outcome: A TRACK-TBI Pilot Study
Introduction: Neuroworsening may be a sign of progressive brain injury and is a factor for treatment of traumatic brain injury (TBI) in intensive care settings. The implications of neuroworsening for clinical management and long-term sequelae of TBI in the emergency department (ED) require characterization. Methods: Adult TBI subjects from the prospective Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study with ED admission and disposition Glasgow Coma Scale (GCS) scores were extracted. All patients received head computed tomography (CT) scan p < 0.001). Neuroworsening subjects had higher likelihoods of cranial surgery (56.3%/3.5%), intracranial pressure (ICP) monitoring (62.5%/2.6%), in-hospital mortality (37.5%/0.6%), and unfavorable 3- and 6-month outcome (58.3%/4.9%; 53.8%/6.2%; all p < 0.001). On multivariable analysis, neuroworsening predicted surgery (mOR = 4.65 [1.02–21.19]), ICP monitoring (mOR = 15.48 [2.92–81.85], and unfavorable 3- and 6-month outcome (mOR = 5.36 [1.13–25.36]; mOR = 5.68 [1.18–27.35]). Conclusions: Neuroworsening in the ED is an early indicator of TBI severity, and a predictor of neurosurgical intervention and unfavorable outcome. Clinicians must be vigilant in detecting neuroworsening, as affected patients are at increased risk for poor outcomes and may benefit from immediate therapeutic interventions.
- 3 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 2024
Open AccessNeuroworsening in the Emergency Department Is a Predictor of Traumatic Brain Injury Intervention and Outcome: A TRACK-TBI Pilot Study
Introduction: Neuroworsening may be a sign of progressive brain injury and is a factor for treatment of traumatic brain injury (TBI) in intensive care settings. The implications of neuroworsening for clinical management and long-term sequelae of TBI in the emergency department (ED) require characterization. Methods: Adult TBI subjects from the prospective Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study with ED admission and disposition Glasgow Coma Scale (GCS) scores were extracted. All patients received head computed tomography (CT) scan p < 0.001). Neuroworsening subjects had higher likelihoods of cranial surgery (56.3%/3.5%), intracranial pressure (ICP) monitoring (62.5%/2.6%), in-hospital mortality (37.5%/0.6%), and unfavorable 3- and 6-month outcome (58.3%/4.9%; 53.8%/6.2%; all p < 0.001). On multivariable analysis, neuroworsening predicted surgery (mOR = 4.65 [1.02–21.19]), ICP monitoring (mOR = 15.48 [2.92–81.85], and unfavorable 3- and 6-month outcome (mOR = 5.36 [1.13–25.36]; mOR = 5.68 [1.18–27.35]). Conclusions: Neuroworsening in the ED is an early indicator of TBI severity, and a predictor of neurosurgical intervention and unfavorable outcome. Clinicians must be vigilant in detecting neuroworsening, as affected patients are at increased risk for poor outcomes and may benefit from immediate therapeutic interventions.
- 11 January 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 108 (1) , 231-234
Demographic and Clinical Factors Affecting Pediatric Survival in South Kivu, the Democratic Republic of the Congo
: Promoting children’s health is challenging in underresourced regions, with worse outcomes in areas of sociopolitical instabilities. This encapsulates the difficulties faced by the Panzi General Referral Hospital (PGRH) in South Kivu, the Democratic Republic of the Congo. In this retrospective, cross-sectional study of 456 children ≤ 18 years who presented to the pediatric emergency department of PGRH between December 2018 and May 2019, we present demographic and clinical predictors that affect pediatric survival. We note that referrals from external clinics (odds ratio [OR], 0.37; 95% CI, 0.18–0.75), poor maternal education (OR, 0.21; 95% CI, 0.07–0.67), diagnoses of meningitis (OR, 0.37; 95% CI, 0.18–0.75) or malnutrition (OR, 0.21; 95% CI, 0.07–0.67) are risk factors hindering pediatric survival. Paternal unemployment or longer durations of hospital stay, on the other hand, are protective toward survival. These predictors confirm the importance of accessibility and availability of medical resources and knowledge as levers to establish an effective, robust network of pediatric care delivery capable of withstanding South Kivu’s unresolved political tumult.
- 11 January 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 108 (1) , 231-234
Demographic and Clinical Factors Affecting Pediatric Survival in South Kivu, the Democratic Republic of the Congo
: Promoting children’s health is challenging in underresourced regions, with worse outcomes in areas of sociopolitical instabilities. This encapsulates the difficulties faced by the Panzi General Referral Hospital (PGRH) in South Kivu, the Democratic Republic of the Congo. In this retrospective, cross-sectional study of 456 children ≤ 18 years who presented to the pediatric emergency department of PGRH between December 2018 and May 2019, we present demographic and clinical predictors that affect pediatric survival. We note that referrals from external clinics (odds ratio [OR], 0.37; 95% CI, 0.18–0.75), poor maternal education (OR, 0.21; 95% CI, 0.07–0.67), diagnoses of meningitis (OR, 0.37; 95% CI, 0.18–0.75) or malnutrition (OR, 0.21; 95% CI, 0.07–0.67) are risk factors hindering pediatric survival. Paternal unemployment or longer durations of hospital stay, on the other hand, are protective toward survival. These predictors confirm the importance of accessibility and availability of medical resources and knowledge as levers to establish an effective, robust network of pediatric care delivery capable of withstanding South Kivu’s unresolved political tumult.
- Open Access
- 14 July 2022
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 3 (3)
Idiopathic Spinal Subarachnoid and Subdural Hemorrhage in a Patient With Eosinophilic Granulomatosis and Polyangiitis
BACKGROUND AND IMPORTANCE: Development of concomitant spontaneous subdural hematoma (SSDH) and spontaneous subarachnoid hemorrhage (SSAH) in the spine without inciting trauma, iatrogenic event, or underlying cerebrovascular malformation is rare. It is rarer still for these to present in a patient with eosinophilic granulomatosus with polyangiitis. CLINICAL PRESENTATION: Herein, we present the case of a 73-year-old woman with a complex medical history, including possible eosinophilic granulomatosus with polyangiitis, who was admitted to the medical intensive care unit at Dartmouth-Hitchcock Medical Center and was found to have concominant SSAH and SSDH. CONCLUSION: This case serves as a review of the common and uncommon symptoms of IS-SAH with SSDH to improve recognition of this acute neurosurgical emergency in the medical intensive care setting.
- 14 July 2022
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 3 (3)
Open AccessIdiopathic Spinal Subarachnoid and Subdural Hemorrhage in a Patient With Eosinophilic Granulomatosis and Polyangiitis
BACKGROUND AND IMPORTANCE: Development of concomitant spontaneous subdural hematoma (SSDH) and spontaneous subarachnoid hemorrhage (SSAH) in the spine without inciting trauma, iatrogenic event, or underlying cerebrovascular malformation is rare. It is rarer still for these to present in a patient with eosinophilic granulomatosus with polyangiitis. CLINICAL PRESENTATION: Herein, we present the case of a 73-year-old woman with a complex medical history, including possible eosinophilic granulomatosus with polyangiitis, who was admitted to the medical intensive care unit at Dartmouth-Hitchcock Medical Center and was found to have concominant SSAH and SSDH. CONCLUSION: This case serves as a review of the common and uncommon symptoms of IS-SAH with SSDH to improve recognition of this acute neurosurgical emergency in the medical intensive care setting.
- 1 June 2022
- Published by Springer Nature in Neurocritical Care
- Vol. 37 (2) , 538-546
The Effect of Antiseizure Medication Administration on Mortality and Early Posttraumatic Seizures in Critically Ill Older Adults with Traumatic Brain Injury
Background Traumatic brain injury (TBI) is a major cause of morbidity and mortality in the United States. Older adults represent an understudied and growing TBI population. Current Brain Trauma Foundation guidelines support prophylactic antiseizure medication (ASM) administration to reduce the risk of early posttraumatic seizures (within 7 days of injury) in patients with severe TBI. Whether ASM decreases mortality or early seizure risk in this population remains unclear. This study addresses the knowledge gap regarding the impact of ASM administration on the risk of seizure or mortality after TBI in patients more than 65 years of age. Methods This retrospective cohort study used a publicly available data set from the Medical Information Mart for Intensive Care-III from the Massachusetts Institute of Technology. Our cohort included patients 65 years or older with a primary exposure of early ASM administration with TBI resulting in an intensive care unit (ICU) admission in a level I trauma center from 2001 to 2012. A double-robust inverse propensity scale weighted model on the basis of proportional hazard and logistic regression models was created to assess the association between ASM administration and risk of death within 7 days of admission to the ICU. Secondary outcomes included 30-day mortality and 1-year mortality, early posttraumatic seizures, ICU length of stay, and hospital length of stay. Results Of 1145 patients 65 years or older with TBI admitted to an ICU, 783 (68.4%) received ASM within the first 24 h. Patients meeting inclusion criteria were predominantly white (83.8%) and were male (52.3%), with a median (interquartile range) age of 81 (74–86) years. TBI severity, classified by Glasgow Coma Score, was predominantly mild (71.2%), followed by moderate (16.8%) and severe (11.3%). Patients who received ASM were less likely to have died at 7 days (adjusted death hazard ratio [HR] = 0.48 [95% confidence interval {CI} 0.28–0.88], P = 0.005), at 30 days (adjusted HR 0.67 [95% CI 0.45–0.99], P = 0.045), and at 1 year (adjusted HR 0.72 [95% CI 0.54–0.97], P = 0.029). Groups were not different in regard to seizure (adjusted seizure odds ratio 1.18 [95% CI 0.61–2.26]) compared with those who did not receive ASM. Conclusions Early ASM administration was associated with reduced mortality at 7 days, 30 days, and 1 year but did not decrease the risk of early seizures among older adults who presented with TBI at an ICU. This benefit was observed in mild, moderate, and severe TBI assessed by Glasgow Coma Score on presentation among patients 65 years old and older and suggests broader recommendations for the use of ASM in older adults who present with TBI of any severity at an ICU.
- 1 June 2022
- Published by Springer Nature in Neurocritical Care
- Vol. 37 (2) , 538-546
The Effect of Antiseizure Medication Administration on Mortality and Early Posttraumatic Seizures in Critically Ill Older Adults with Traumatic Brain Injury
Background Traumatic brain injury (TBI) is a major cause of morbidity and mortality in the United States. Older adults represent an understudied and growing TBI population. Current Brain Trauma Foundation guidelines support prophylactic antiseizure medication (ASM) administration to reduce the risk of early posttraumatic seizures (within 7 days of injury) in patients with severe TBI. Whether ASM decreases mortality or early seizure risk in this population remains unclear. This study addresses the knowledge gap regarding the impact of ASM administration on the risk of seizure or mortality after TBI in patients more than 65 years of age. Methods This retrospective cohort study used a publicly available data set from the Medical Information Mart for Intensive Care-III from the Massachusetts Institute of Technology. Our cohort included patients 65 years or older with a primary exposure of early ASM administration with TBI resulting in an intensive care unit (ICU) admission in a level I trauma center from 2001 to 2012. A double-robust inverse propensity scale weighted model on the basis of proportional hazard and logistic regression models was created to assess the association between ASM administration and risk of death within 7 days of admission to the ICU. Secondary outcomes included 30-day mortality and 1-year mortality, early posttraumatic seizures, ICU length of stay, and hospital length of stay. Results Of 1145 patients 65 years or older with TBI admitted to an ICU, 783 (68.4%) received ASM within the first 24 h. Patients meeting inclusion criteria were predominantly white (83.8%) and were male (52.3%), with a median (interquartile range) age of 81 (74–86) years. TBI severity, classified by Glasgow Coma Score, was predominantly mild (71.2%), followed by moderate (16.8%) and severe (11.3%). Patients who received ASM were less likely to have died at 7 days (adjusted death hazard ratio [HR] = 0.48 [95% confidence interval {CI} 0.28–0.88], P = 0.005), at 30 days (adjusted HR 0.67 [95% CI 0.45–0.99], P = 0.045), and at 1 year (adjusted HR 0.72 [95% CI 0.54–0.97], P = 0.029). Groups were not different in regard to seizure (adjusted seizure odds ratio 1.18 [95% CI 0.61–2.26]) compared with those who did not receive ASM. Conclusions Early ASM administration was associated with reduced mortality at 7 days, 30 days, and 1 year but did not decrease the risk of early seizures among older adults who presented with TBI at an ICU. This benefit was observed in mild, moderate, and severe TBI assessed by Glasgow Coma Score on presentation among patients 65 years old and older and suggests broader recommendations for the use of ASM in older adults who present with TBI of any severity at an ICU.